Abstract
Successful delivery of nano-particles to the lung has to take account of the potential biological and pathophysiological barriers of the target organ. Hence this review attempts to provide an overview of the anatomy, physiology, and pathophysiology of the lung. In particular, pathological changes may have crucial impact on successful nano-carrier delivery. The latest approaches in nano-encapsulation and pulmonary delivery will be discussed for small molecular drugs, usually having a fast release due to short diffusion distances. In peptide and protein delivery, the stability of organic solvents and prevention from denaturation are main aspects which are addressed. Gene delivery may be divided into DNA, mRNA and siRNA delivery. They have in common that most of the polymers used still have toxic effects and are only poorly degradable. Polymers with reduced toxic potential and biodegradable polyamides will be presented in this review. The attractiveness of pulmonary drug delivery both for loco-regional and systemic application is likely to increase in the future as nano-carriers may allow more efficient and selective drug deposition in the lung.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
